Impax Laboratories — Q2 2016 Earnings Presentation
28 slides from Impax Laboratories's earnings presentation, Aug 9, 2016
Slide 1: Second Quarter 2016 Earnings Conference Call
1 Second Quarter 2016 Earnings Conference Call August 9, 2016
Slide 2: Cautionary Statement Regarding Forward Looking Statements
2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and
Slide 3: Agenda
3 Agenda • 2Q16 Financial Results • Business Update Fred Wilkinson President & CEO • 2Q16 Financial Review • 2016 Financial Guidance Update Bryan Reasons SVP & CFO • Q&A Executive Team
Slide 4: 2Q16 Results and Business Update
4 2Q16 Results and Business Update Fred Wilkinson President & Chief Executive Officer
Slide 5: 2Q16 Financial Results
5 2Q16 Financial Results $175 $122 2Q15 2Q16 Generic Revenues $ millions $40 $51 2Q15 2Q16 • $53MM decline in sales of generics Solaraze®, Skelaxin® and Adderall XR® • Significant decline in price and volume on gSolaraze and gSkelaxin due to new competition led to a $15 million shelf-stock adjustmen
Slide 6: Revised 2016 Financial Guidance
6 Revised 2016 Financial Guidance • What has changed since mid-June? › Further deterioration in generic Solaraze® market as a result of aggressive competition › Delayed close of the generic product acquisition from Teva/Allergan › Delay in supply of an authorized generic product and deferred timing
Slide 7: Rapid Market Change in Generic Solaraze
7 Rapid Market Change in Generic Solaraze® (Diclofenac Sodium Gel 3%) Impax Net Sales ($ in millions) 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 Impax Net Sales $11 $17 $33 $88 $50 $5 Sequential $ Change +$3 +$6 +$16 +$55 ($38) ($45) Change in Sales Due to a Change in Volume and / or Price Volume 100% 100% 100%
Slide 8: Largest Generic Products – LTM Share
8 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2015/07/24 2015/08/21 2015/09/18 2015/10/16 2015/11/13 2015/12/11 2016/01/08 2016/02/05 2016/03/04 2016/04/01 2016/04/29 2016/05/27 2016/06/24 Amphetamine Salts XR (A) Amphetamine Salts IR (B) Diclofenac Sodium Gel (C) Digoxin (D) Epinephrine Auto-inject
Slide 9: Year Over Year Change in Generic Volume and Price
9 Impax Year Over Year Change in Generic Volume and Price Total Generics 3Q15 4Q15 1Q16 2Q16 Volume 27% 106% 53% (11%) Price (3%) (13%) (21%) (19%) gSolaraze® (Diclofenac sodium gel 3%); gSkelaxin® (Metaxalone) Excluding generic Solaraze® and generic Skelaxin® 3Q15 4Q15 1Q16 2Q16 Volume (4%) 12% 4%
Slide 10: Expanded Generic Portfolio Through Product Acquisition
10 Expanded Generic Portfolio Through Product Acquisition Acquired 15 Marketed Products Product Brand Strength Divested File Acitretin capsules Soriatane® 10 mg,17.5 mg, 22.5 mg, 25 mg Allergan Alendronate Sodium tablets Fosamax® 5mg, 10mg, 35 mg, 40 mg, 70 mg Teva Budesonide inhalation suspension P
Slide 11: Targeted Generic Product Launches in 2016
11 Targeting 12 to 14 Generic Product Launches in 2016 Source of sales data: IMS NPA June 2016; Launch/Approval data as of Aug 3, 2016; TA = Tentative Approval (1) Assuming receipt of final FDA approval launch following patent expiration in April 2017 (2) Launched Hayward ANDA U.S. Brand/Generic mar
Slide 12: Multiple Generic Opportunities to Drive Future Growth
12 Multiple Generic Opportunities to Drive Future Growth Solid Oral Dosage Alternative Dosage Form Current U.S. Brand/Generic Market - $9B 30% Potential/Confirmed FTF or FTM Source of sales data: IMS NPA June 2016; Pipeline data as of Aug 3, 2016; TA = Tentative Approval Current U.S. Brand/Generic M
Slide 13: Focused on Growing CNS Franchise
13 Focused on Growing CNS Franchise 0.0% 1.0% 2.0% 3.0% 0 2,000 4,000 6,000 8,000 10,000 12,000 F eb -1 5 M ar -1 5 A pr -1 5 M ay -1 5 Ju n- 15 Ju l-1 5 A ug -1 5 S ep -1 5 O ct -1 5 N ov -1 5 D ec -1 5 Ja n- 16 F eb -1 6 M ar -1 6 A pr -1 6 M ay -1 6 Ju n- 16 C D LD S ha re T R x Monthly TRx and S
Slide 14: Accelerating Non-Personal Promotion
14 Accelerating Non-Personal Promotion 0% 20% 40% 0 1,000 2,000 3,000 4,000 A nt he lm in ti c S ha re T R x Weekly TRx and Combined Share of Anthelmintic TRx Since Launch Albenza TRx Emverm TRx Combined EM and AL Sh (albendazole) tablets & • Launched Emverm (mebendazole) • Building awareness that m
Slide 15: IPX203: Positive Outcome of Phase 2a Study
15 IPX203: Positive Outcome of Phase 2a Study • Phase 2a study › Randomized, crossover, single-dose, rater-blinded pharmacodynamics study in advanced Parkinson's Patients. › IPX203 was compared to both immediate-release carbidopa- levodopa (IR CD-LD) and Rytary® › Endpoints: Investigator Assessment
Slide 16: 2016 Priorities
16 2016 Priorities • Maintain quality and compliance across all facilities / departments • Sharpen focus on supply chain and cost efficiencies • Improve conversion costs across global manufacturing network Focus on Quality and Operations • Optimize existing generic opportunities • Launch up to 12 to
Slide 17: Financial Review and 2016 Financial Guidance
17 Financial Review and 2016 Financial Guidance Bryan Reasons Senior Vice President & Chief Financial Officer
Slide 18: 2Q 2016 Financial Results
18 2Q 2016 Financial Results 2Q 2016 2Q 2015 Change GENERIC DIVISION Total Revenues $121.7 $174.7 (30.3%) Gross Margin 30.7% 36.6% (5.9)ppts Adjusted Gross Margin 40.2% 43.1% (2.9)ppts Operating Income $18.5 $42.4 (56.4%) Adjusted Operating Income $31.1 $53.7 (42.1%) SPECIALTY PHARMA DIVISION Total
Slide 19: 2016 Updated Guidance
19 2016 Updated Guidance Item 2015A Issued February 22 Revised June 21 – Generic Product Acquisition Updated August 9 Revenue $860M At least 15% over 2015 (~$990M) No Change $900M to $940M Adjusted Gross Margin 49% Approximately 50% Low 50% range No change Adjusted R&D Expense $74M $100M-$105M No ch
Slide 20: Well-Positioned Capital Structure Post-Acquisition
20 Well-Positioned Capital Structure Post-Acquisition Generic Product Acquisition Financing $400 Million Term Loan A; Interest Rate of L+300*; Tenor 5 years Capitalization ($ millions) Cash and Cash Equivalents – June 30, 2016 $ 367 Less Cash Used for Acquisition $ 196 Revolver ($200) $ 0 2022 Conve
Slide 21: Focused on Creating Long-Term Growth
21 $512M $596M $860M $0.82 $1.32 $1.45 54% 59% 49% $0.00 $0.20 $0.40 $0.60 $0.80 $1.00 $1.20 $1.40 $1.60 $1.80 $2.00 $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 $1,000 2013 2014 2015 2016 Focused on Creating Long-Term Growth 2011 – 2015 FDA Warning Letter at Hayward Facility $900M to $940M $1.57
Slide 22: Q&A
22 Q&A
Slide 23: Appendix
23 Appendix
Slide 24: Pending ANDAs at FDA
24 22 Pending ANDAs at FDA * Assuming final FDA approval, earliest potential launch date/timing based on settlement or patent expiration date. Source of sales data: IMS NPA Monthly June 2016; Pipeline data as of June 21, 2016; TA = tentative approval 1 Launched authorized generic in April 2016 2 Lau
Slide 25: GAAP to Adjusted Net Income Reconciliation
25 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. (Unaudited, amounts in thousands, except per share and per share data) Three months ended June 30, 2016 2015 Net loss $ (2,701) $ (1,852) Adjusted to add (deduct): Amortization 12,4
Slide 26: GAAP to Adjusted Results Reconciliation
26 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues to adjusted cost of revenues. (Unaudited, amounts in thousands) Three months ended June 30, 2016 2015 Cost of revenues $ 99,606 $ 129,331 Adjusted to deduct: Amortization 12,469 12,622 H
Slide 27: Generic Division GAAP to Adjusted Results Reconciliation
27 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousands) (a) Adjusted gr
Slide 28: Specialty Pharma Division GAAP to Adjusted Results Reconciliation
28 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Divisions reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousand